Tvardi Therapeutics Plunges 16.6% on Revenue Growth Concerns

On April 17, 2025, Tvardi Therapeutics experienced a significant drop of 16.6% in pre-market trading, reflecting a notable decline in investor sentiment.

Tvardi Therapeutics, a clinical-stage biopharmaceutical company, is focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC). The company's second product candidate, TTI-109, is designed to enhance the ability to target STAT3, showcasing its commitment to innovative therapeutic solutions.

Analysts have provided a revenue growth forecast of -25.0% for the fiscal year 2025, based on top analyst calls. This forecast indicates a challenging outlook for the company's financial performance, which may have contributed to the recent stock price decline. The negative growth projection suggests that investors are cautious about the company's ability to generate revenue in the near term.

Tvardi Therapeutics' stock price has seen a significant decrease of 28.60% over the past 52 weeks, highlighting a prolonged period of underperformance. This long-term decline in stock price reflects broader concerns about the company's prospects and its ability to deliver on its therapeutic promises. The company's market capitalization of $170.73 million further underscores its status as a micro-cap stock, which can be more volatile and subject to greater market fluctuations.